Perkin Elmer has unveiled its Solaris quantitative optical molecular imaging system for use in small and large animal studies.
The Solaris system, when combined with PerkinElmer’s suite of fluorescence molecular imaging probes, can bridge molecular imaging research techniques to support potential clinical outcomes.
By distinguishing healthy versus diseased tissue in real-time, researchers can more accurately and completely map tumours, the company claims.
“The Solaris system is our latest breakthrough translational quantitative imaging solution designed to facilitate disease studies and advance next-generation, molecular-level surgical support research,” said Brian Kim, president, life sciences & technology, Perkin Elmer.
“Translational drug discovery validation in large animal models enhances toxicity and efficacy predictability in humans and provides critical knowledge for drug development programmes.”
The Solaris system is designed for ambient lighting conditions found in preclinical surgical research suites and can dynamically use a broad and versatile range of fluorescent probes, offering flexibility for translational researchers when targeting diseases.
Its research applications include drug efficacy, drug safety, measurement of real-time biological therapeutic responses, and advanced molecular-guided surgery applications such as surgical tumour margin determination in live animal models.
